Familial Hypercholesterolemia

A study published in the European Journal of Preventive Cardiology found that patients with familial hypercholesterolemia may have elevated risk for developing eating disorders.

When discussing high cholesterol with patients, physicians should consider the possibility of familial hypercholesterolemia, according to Ijeoma Isiadinso, MD, MPH, FACC, FASNC.

Long-term adherence to PCSK9 inhibition was high among a high-risk cohort with familial hypercholesterolemia, which improved LDL goal attainment when added on top of background statin therapy and ezetimibe, researchers reported.

Lipoprotein(a) levels of 67 mg/dL or more may be indicative of similar risk for premature MI as LDL of 180 mg/dL or more in patients with familial hypercholesterolemia, researchers reported.

Among younger patients with ACS, approximately one in 11 had familial hypercholesterolemia, researchers reported in The American Journal of Cardiology.

In a cohort of patients with familial hypercholesterolemia, women were less likely than men to receive high-intensity treatment and reach LDL goals, according to data presented at the National Lipid Association Scientific Sessions.

People with familial hypercholesterolemia and those on long-term, high-intensity statins had no greater risk for dementia than matched controls, per a study published in JAMA Network Open.

In patients with heterozygous familial hypercholesterolemia already taking maximally tolerated lipid-lowering medication, resmetirom lowered LDL, triglycerides, apolipoprotein B and lipoprotein(a) levels vs. placebo, researchers reported.